Target family: Adrenoceptors (type: gpcr)
Target: &beta;<sub>2</sub>-adrenoceptor

Ligand: 7-methylcyanopindolol (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Primary target: no
Median affinity: 10.399999618530273 pKd
Reference (Journal): Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound &#x3b2;1-Adrenergic Receptor.
Published in: Mol Pharmacol

Ligand: abediterol (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: yes
Median affinity: 9.220000267028809 pIC50
Reference (Journal): Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.
Published in: J Pharmacol Exp Ther

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: no
Median affinity: 7.900000095367432 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: no
Median affinity:  pKi
Reference (Journal): beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists.
Published in: J Biol Chem

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: no
Median affinity:  pKi
Reference (Journal): Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors.
Published in: Proc Natl Acad Sci USA

Ligand: (-)-adrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (no history prior to 1951)
Primary target: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: alprenolol (Synthetic organic)
Interaction type: Antagonist
Action: Partial agonist
Ligand approved: yes
Primary target: yes
Median affinity: 9 pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: AS408 (Synthetic organic)
Interaction type: Allosteric modulator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): An allosteric modulator binds to a conformational hub in the β<sub>2</sub> adrenergic receptor.
Published in: Nat Chem Biol

Ligand: atenolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: atenolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: betaxolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: betaxolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: no
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: betaxolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: no
Median affinity:  pKi
Reference (Journal): Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes.
Published in: J Ocul Pharmacol Ther

Ligand: BI-167107 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 10 pEC50
Reference (Journal): Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists.
Published in: Bioorg Med Chem Lett

Ligand: BRL35135 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: BRL35135 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: BRL 37344 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 6.5 pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: BRL 37344 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 6.900000095367432 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: bunolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1985)
Primary target: yes
Median affinity: 9.260000228881836 pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: bupranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: bupranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: bupranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Potent and selective human beta(3)-adrenergic receptor antagonists.
Published in: J Pharmacol Exp Ther

Ligand: butoxamine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Depolarization of rat isolated superior cervical ganglia mediated by beta 2-adrenoceptors.
Published in: Br J Pharmacol

Ligand: butoxamine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKB
Reference (Journal): Depolarization of rat isolated superior cervical ganglia mediated by beta 2-adrenoceptors.
Published in: Br J Pharmacol

Ligand: butoxamine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.449999809265137 pKB
Reference (Journal): Functional characterization of the beta-adrenergic receptor subtypes expressed by CA1 pyramidal cells in the rat hippocampus.
Published in: J Pharmacol Exp Ther

Ligand: butoxamine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents.
Published in: Jpn J Pharmacol

Ligand: butoxamine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKB
Reference (Journal): Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents.
Published in: Jpn J Pharmacol

Ligand: carazolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: carazolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity:  pKi
Reference (Journal): Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds.
Published in: Bioorg Med Chem Lett

Ligand: carvedilol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1995)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Potent and selective human beta(3)-adrenergic receptor antagonists.
Published in: J Pharmacol Exp Ther

Ligand: carvedilol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1995)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: CGP 12177 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: CGP 12177 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: CGP 12177 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pKi
Reference (Journal): Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.
Published in: Br J Pharmacol

Ligand: CHF-6366 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 11.399999618530273 pKd
Reference (Journal): Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β<sub>2</sub> Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases.
Published in: J Med Chem

Ligand: cicloprolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.2 pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: cimaterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: clenbuterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: clenbuterol (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: clenbuterol (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Salmeterol's extreme &#x3b2;2 selectivity is due to residues in both extracellular loops and transmembrane domains.
Published in: Mol Pharmacol

Ligand: clenbuterol (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Synthesis and pharmacological characterization of beta2-adrenergic agonist enantiomers: zilpaterol.
Published in: J Med Chem

Ligand: compound 6 [PMID: 29769246] (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Unique Positive Cooperativity Between the <i>&#x3b2;</i>-Arrestin-Biased <i>&#x3b2;</i>-Blocker Carvedilol and a Small Molecule Positive Allosteric Modulator of the <i>&#x3b2;</i>2-Adrenergic Receptor.
Published in: Mol Pharmacol

Ligand: ephedrine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (2020)
Primary target: yes
Median affinity: 5.599999904632568 pKi
Reference (Journal): beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists.
Published in: J Biol Chem

Ligand: fenoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Salmeterol's extreme &#x3b2;2 selectivity is due to residues in both extracellular loops and transmembrane domains.
Published in: Mol Pharmacol

Ligand: fenoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Discovery of β2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor.
Published in: ACS Med Chem Lett

Ligand: fenoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): &#x3b2;<sub>2</sub> -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the &#x3b2;<sub>2</sub> -adrenoceptor with possible implications for the treatment of asthma.
Published in: Br J Pharmacol

Ligand: fenoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: no
Median affinity:  pEC50
Reference (Journal): &#x3b2;<sub>2</sub> -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the &#x3b2;<sub>2</sub> -adrenoceptor with possible implications for the treatment of asthma.
Published in: Br J Pharmacol

Ligand: fenoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: no
Median affinity:  pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: fenoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: formoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2001)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: formoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2001)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): Long-chain formoterol analogues: an investigation into the effect of increasing amino-substituent chain length on the beta2-adrenoceptor activity.
Published in: Bioorg Med Chem Lett

Ligand: formoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2001)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): Recruitment of &#x3b2;-arrestin 1 and 2 to the &#x3b2;2-adrenoceptor: analysis of 65 ligands.
Published in: J Pharmacol Exp Ther

Ligand: formoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2001)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
Published in: J Pharmacol Exp Ther

Ligand: formoterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2001)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): Salmeterol's extreme &#x3b2;2 selectivity is due to residues in both extracellular loops and transmembrane domains.
Published in: Mol Pharmacol

Ligand: ICI 118551 (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: ICI 118551 (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: ICI 118551 (Synthetic organic)
Interaction type: Antagonist
Action: Inverse agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses.
Published in: Mol Pharmacol

Ligand: indacaterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA (2009), FDA (2011)
Primary target: no
Median affinity: 8.100000381469727 pEC50
Reference (Journal): In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
Published in: J Pharmacol Exp Ther

Ligand: indacaterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA (2009), FDA (2011)
Primary target: yes
Median affinity:  pKi
Reference (Journal): In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
Published in: J Pharmacol Exp Ther

Ligand: indacaterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA (2009), FDA (2011)
Primary target: yes
Median affinity:  pKi
Reference (Journal): An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.
Published in: Bioorg Med Chem Lett

Ligand: isoprenaline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.
Published in: Br J Pharmacol

Ligand: isoprenaline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: isoprenaline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: no
Median affinity: 8.199999809265137 pEC50
Reference (Journal): Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.
Published in: Br J Pharmacol

Ligand: isoprenaline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: no
Median affinity: 8.199999809265137 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: isoprenaline (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: labetalol (Synthetic organic)
Interaction type: Antagonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: yes
Median affinity: 7.960000038146973 pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: labetalol (Synthetic organic)
Interaction type: Antagonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1984)
Primary target: yes
Median affinity: 7.960000038146973 pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: LK 204-545 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.2 pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: metoprolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: no
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: metoprolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: mirabegron (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA and EMA (2012)
Primary target: no
Median affinity: 5 pEC50
Reference (Journal): The metabolic effects of mirabegron are mediated primarily by &#x3b2;<sub>3</sub> -adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: mirabegron (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA and EMA (2012)
Primary target: no
Median affinity: 5 pEC50
Reference (Journal): Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
Published in: J Pharmacol Exp Ther

Ligand: mirabegron (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA and EMA (2012)
Primary target: no
Median affinity:  pEC50
Reference (Journal): Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.
Published in: J Pharmacol Exp Ther

Ligand: mirabegron (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA and EMA (2012)
Primary target: no
Median affinity:  pEC50
Reference (Journal): The metabolic effects of mirabegron are mediated primarily by &#x3b2;<sub>3</sub> -adrenoceptors.
Published in: Pharmacol Res Perspect

Ligand: nadolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1979)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Potent and selective human beta(3)-adrenergic receptor antagonists.
Published in: J Pharmacol Exp Ther

Ligand: nadolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1979)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: nebivolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2007)
Primary target: no
Median affinity:  pKi
Reference (Journal): Lack of evidence that nebivolol is a β₃-adrenoceptor agonist.
Published in: Eur J Pharmacol

Ligand: nebivolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (2007)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: NIHP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6 pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: NIP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.5 pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  pKi
Reference (Journal): Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.
Published in: Naunyn Schmiedebergs Arch Pharmacol

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  pKi
Reference (Journal): Structural basis of beta-adrenergic receptor subtype specificity studied with chimeric beta 1/beta 2-adrenergic receptors.
Published in: Proc Natl Acad Sci USA

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity: 6.400000095367432 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: (-)-noradrenaline (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1950)
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: noradrenaline (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5.4 pKi
Reference (Journal): Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the beta2 adrenergic receptor.
Published in: Mol Pharmacol

Ligand: olodaterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2014)
Primary target: yes
Median affinity: 10 pEC50
Reference (Journal): Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models.
Published in: J Pharmacol Exp Ther

Ligand: orciprenaline (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (1973)
Primary target: yes
Median affinity: 5.320000171661377 pKd
Reference (Journal): Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.
Published in: Eur J Med Chem

Ligand: pindolol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1982)
Primary target: yes
Median affinity: 9.399999618530273 pKi
Reference (Journal): Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
Published in: Bioorg Med Chem Lett

Ligand: pindolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1982)
Primary target: no
Median affinity: 9.399999618530273 pKi
Reference (Journal): Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists.
Published in: Bioorg Med Chem Lett

Ligand: procaterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: no
Median affinity: 7.099999904632568 pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: procaterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Primary target: yes
Median affinity: 8.430000305175781 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: propafenone (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1989)
Primary target: no
Median affinity: 7.440000057220459 pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: propranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1967), EMA (2014)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: propranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1967), EMA (2014)
Primary target: yes
Median affinity:  pKi
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: propranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1967), EMA (2014)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
Published in: Mol Pharmacol

Ligand: propranolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1967), EMA (2014)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Influence of agonist efficacy and receptor phosphorylation on antagonist affinity measurements: differences between second messenger and reporter gene responses.
Published in: Mol Pharmacol

Ligand: ractopamine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: ractopamine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: ractopamine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): &#x3b2;<sub>2</sub> -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the &#x3b2;<sub>2</sub> -adrenoceptor with possible implications for the treatment of asthma.
Published in: Br J Pharmacol

Ligand: ractopamine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
Published in: Mol Pharmacol

Ligand: ractopamine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): &#x3b2;<sub>2</sub> -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the &#x3b2;<sub>2</sub> -adrenoceptor with possible implications for the treatment of asthma.
Published in: Br J Pharmacol

Ligand: salbutamol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Cell-based and in-silico studies on the high intrinsic activity of two boron-containing salbutamol derivatives at the human β₂-adrenoceptor.
Published in: Bioorg Med Chem

Ligand: salbutamol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity:  pEC50
Reference (Journal): &#x3b2;<sub>2</sub> -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the &#x3b2;<sub>2</sub> -adrenoceptor with possible implications for the treatment of asthma.
Published in: Br J Pharmacol

Ligand: salbutamol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Salmeterol's extreme &#x3b2;2 selectivity is due to residues in both extracellular loops and transmembrane domains.
Published in: Mol Pharmacol

Ligand: salbutamol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity:  pKi
Reference (Journal): &#x3b2;<sub>2</sub> -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the &#x3b2;<sub>2</sub> -adrenoceptor with possible implications for the treatment of asthma.
Published in: Br J Pharmacol

Ligand: salbutamol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
Published in: Mol Pharmacol

Ligand: salbutamol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: salbutamol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity:  pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: salbutamol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: salmeterol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1994), EMA (2016)
Primary target: no
Median affinity:  pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: salmeterol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1994), EMA (2016)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: salmeterol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1994), EMA (2016)
Primary target: yes
Median affinity:  pKi
Reference (Journal): &#x3b2;<sub>2</sub> -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the &#x3b2;<sub>2</sub> -adrenoceptor with possible implications for the treatment of asthma.
Published in: Br J Pharmacol

Ligand: salmeterol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1994), EMA (2016)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Salmeterol's extreme &#x3b2;2 selectivity is due to residues in both extracellular loops and transmembrane domains.
Published in: Mol Pharmacol

Ligand: salmeterol (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1994), EMA (2016)
Primary target: no
Median affinity:  pEC50
Reference (Journal): In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action.
Published in: J Pharmacol Exp Ther

Ligand: solabegron (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.900000095367432 pEC50
Reference (Journal): Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
Published in: J Med Chem

Ligand: sotalol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1992)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: sotalol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1992)
Primary target: yes
Median affinity:  pKi
Reference (Webpage): National Toxicology Program: Dept of Health and Human Services.

Ligand: SR59230A (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: SR59230A (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Potent and selective human beta(3)-adrenergic receptor antagonists.
Published in: J Pharmacol Exp Ther

Ligand: [125I]ICYP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting &#x3b2;2-adrenoceptor agonists.
Published in: Br J Pharmacol

Ligand: [125I]ICYP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: [125I]ICYP (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
Published in: Eur J Pharmacol

Ligand: [3H]CGP12177 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 9.84000015258789 pKd
Reference (Journal): Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.
Published in: Br J Pharmacol

Ligand: [3H]CGP12177 (Synthetic organic)
Interaction type: Antagonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 9.800000190734863 pKd
Reference (Journal): Pharmacological characterization of CGP 12177 at the human beta(2)-adrenoceptor.
Published in: Br J Pharmacol

Ligand: [3H]dihydroalprenolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 10.100000381469727 pKd
Reference (Journal): Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting &#x3b2;2-adrenoceptor agonists.
Published in: Br J Pharmacol

Ligand: terbutaline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: terbutaline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: yes
Median affinity:  pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: terbutaline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: no
Median affinity: 7.300000190734863 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: timolol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity: 9.699999809265137 pKi
Reference (Journal): The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Published in: Br J Pharmacol

Ligand: vilanterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2013)
Primary target: yes
Median affinity: 9.399999618530273 pEC50
Reference (Journal): Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.
Published in: J Med Chem

Ligand: zinterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.479999542236328 pEC50
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: zinterol (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8 pKi
Reference (Journal): The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.
Published in: Br J Pharmacol

Ligand: Zn2+ (Inorganic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Median affinity: 5.3 pKi
Reference (Journal): Allosteric modulation of beta2-adrenergic receptor by Zn(2+).
Published in: Mol Pharmacol

Ligand: Zn2+ (Inorganic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: no
Median affinity: 3.299999952316284 pKi
Reference (Journal): Identification of an allosteric binding site for Zn2+ on the beta2 adrenergic receptor.
Published in: J Biol Chem

Ligand: Zn2+ (Inorganic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Median affinity: 5.3 pKi
Reference (Journal): Identification of an allosteric binding site for Zn2+ on the beta2 adrenergic receptor.
Published in: J Biol Chem

Ligand: Zn2+ (Inorganic)
Interaction type: Allosteric modulator
Action: Negative
Ligand approved: no
Primary target: no
Median affinity: 3.299999952316284 pKi
Reference (Journal): Allosteric modulation of beta2-adrenergic receptor by Zn(2+).
Published in: Mol Pharmacol